- Home
- NNAVW vs SNY Comparison
NNAVW vs SNY Comparison
Compare NNAVW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNAVW
- SNY
- Stock Information
- Founded
- NNAVW 2007
- SNY 1994
- Country
- NNAVW United States
- SNY France
- Employees
- NNAVW 96
- SNY N/A
- Industry
- NNAVW Industrial Machinery/Components
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NNAVW Industrials
- SNY Health Care
- Exchange
- NNAVW Nasdaq
- SNY Nasdaq
- Market Cap
- NNAVW N/A
- SNY 123.6B
- IPO Year
- NNAVW N/A
- SNY N/A
- Fundamental
- Price
- NNAVW $4.89
- SNY $53.72
- Analyst Decision
- NNAVW
- SNY Buy
- Analyst Count
- NNAVW 0
- SNY 2
- Target Price
- NNAVW N/A
- SNY $62.50
- AVG Volume (30 Days)
- NNAVW 53.1K
- SNY 3.6M
- Earning Date
- NNAVW 03-12-2025
- SNY 04-24-2025
- Dividend Yield
- NNAVW N/A
- SNY 3.05%
- EPS Growth
- NNAVW N/A
- SNY 39.56
- EPS
- NNAVW N/A
- SNY 5.45
- Revenue
- NNAVW $4,963,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- NNAVW N/A
- SNY $5.35
- Revenue Next Year
- NNAVW N/A
- SNY $6.69
- P/E Ratio
- NNAVW N/A
- SNY $9.68
- Revenue Growth
- NNAVW 43.44
- SNY N/A
- 52 Week Low
- NNAVW $4.47
- SNY $45.80
- 52 Week High
- NNAVW $4.70
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NNAVW N/A
- SNY 53.35
- Support Level
- NNAVW N/A
- SNY $52.23
- Resistance Level
- NNAVW N/A
- SNY $53.70
- Average True Range (ATR)
- NNAVW 0.00
- SNY 1.23
- MACD
- NNAVW 0.00
- SNY 0.39
- Stochastic Oscillator
- NNAVW 0.00
- SNY 98.61
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.